Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MIRA Pharmaceuticals, Inc. - Common Stock (NQ: MIRA )

1.290 +0.030 (+2.38%)
Streaming Delayed Price Updated: 11:30 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MIRA Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
MIRA Pharmaceuticals stock rises as new preclinical data reveal its oral ketamine analog Ketamir-2 is 60% more effective than gabapentin in pain relief. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game
Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game 
Via News Direct
Topics Cannabis
Exposures Cannabis
Why Mira Shares Are Trading Higher Today
MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) shares are trading higher Friday following the announcement of promising new preclinical data for its lead development product, Ketamir-2. Here's what you need... 
Via Benzinga
Peering Into Mira Pharmaceuticals's Recent Short Interest
Via Benzinga
(MIRA) - Analyzing Mira Pharmaceuticals's Short Interest
Via Benzinga
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025 
Via News Direct
The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End
The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End 
Via News Direct
MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
MIRA Pharmaceuticals stock surges on promising preclinical results of oral ketamine analog, Ketamir-2, showing 100% pain threshold normalization in rats, positioning it as a potential breakthrough for... 
Via Benzinga
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Heico, PDD Holdings And 3 Stocks To Watch Heading Into Monday
Via Benzinga
MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024
MIRA stock results show that Mira Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?
A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here's a look at the others. 
Via Benzinga
MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year
MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year 
Via News Direct
Topics Cannabis
Exposures Cannabis
Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data
MIRA Pharmaceuticals stock surged on Thursday following new preclinical data on Ketamir-2, MIRA's novel oral ketamine analog, highlighting its unique selectivity and favorable safety profile for... 
Via Benzinga
Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?
Mira Pharmaceuticals stock is falling on Tuesday but that's only after shares of MIRA underwent a massive rally on Monday. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning! 
Via InvestorPlace
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?
MIRA Pharmaceuticals stock is up on Monday after the company posted results from a pre-clinical trial of its novel oral ketamine analog. 
Via InvestorPlace
Dow Edges Lower; Verizon Shares Fall After Q2 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders
MIRA Pharmaceuticals reveals preclinical data for its novel oral ketamine analog, Ketamir-2, targeting neurological and neuropsychiatric disorders. With superior oral absorption and efficacy, Ketamir-2... 
Via Benzinga
Nasdaq Gains 1%; Chicago Fed National Activity Falls In June
Via Benzinga
Topics Economy
Exposures Interest Rates
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Mira Pharmaceuticals Stock Is Moving Higher Monday
MIRA Pharmaceuticals said testing confirmed MIRA's preliminary beliefs regarding a new potential treatment for neurological and neuropsychiatric disorders. 
Via Benzinga
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.